高级检索

    4种新型抗癫痫药的临床疗效评估及血药浓度参考范围的建立

    Clinical Efficacy Evaluation and Establishment of Reference Ranges for Plasma Concentrations of 4 New Antiepileptics

      摘要
    • 摘要:
      目的 通过分析拉考沙胺(lacosamide，LCM)、左乙拉西坦(levetiracetam，LEV)、奥卡西平(oxcarbazepine，OXC)和拉莫三嗪(lamotrigine，LTG)血药浓度、疗效和安全性间的相关性，并建立其有效血药浓度参考范围。
      方法 收集722、1055、1215、680例服用LCM、LEV、OXC和LTG的癫痫患儿的血液样本。采用超高效液相色谱法测定其血药浓度，分析4种抗癫痫药给药剂量与血药浓度的相关性，同时探讨其治疗癫痫患儿临床疗效的影响因素，并建立癫痫患儿的LCM、LEV、OXC和LTG稳态血药浓度参考区间。
      结果 LCM、LEV、OXC和LTG治疗有效率分别为77.7%、82.7%、76.7%和76.6%；不良反应发生率分别为34.8%、33.5%、25.7%和32.1%。OXC和LTG给药剂量与血药浓度的相关性较好(r>0.6)，LCM和LEV给药剂量与血药浓度的相关性均较差(r<0.5)。LCM、LEV、OXC和LTG血药浓度对于疗效的预判准确性 AUC(95%CI)=0.535、0.579、0.526和0.617均高于给药剂量AUC(95%CI)=0.484、0.488、0.477和0.483。癫痫患儿的LCM、LEV、OXC和LTG血药浓度参考范围分别为2.0~15.0 μg·mL−1、8.2~24.2 μg·mL−1、9.8~31.9 μg·mL−1和2.1~15.2 μg·mL−1。
      结论 临床有必要定期监测癫痫患儿的LCM、LEV、OXC和LTG血药浓度，以确保其控制在治疗范围内，以便于及时调整给药剂量，预防药物蓄积过量，从而减少不良反应发生率。

       

      Abstract:
      OBJECTIVE To analyze the correlation between the plasma concentrations, efficacy, and safety of lacosamide(LCM), levetiracetam(LEV), oxcarbazepine(OXC) and lamotrigine(LTG), and to establish a reference range for their effective plasma concentrations.
      METHODS Blood samples were collected from 722, 1055, 1215, and 680 pediatric epilepsy patients taking LCM, LEV, OXC and LTG, respectively. This study used ultra-high performance liquid chromatography to determined plasma concentrations and analyzed the correlation between the dosages and plasma concentrations of LCM, LEV, OXC and LTG. At the same time, this study explored the factors affecting the efficacy of LCM, LEV, OXC and LTG in children with epilepsy, and established the reference ranges for their plasma concentrations.
      RESULTS The efficacy rates of LCM, LEV, OXC and LTG were 77.7%, 82.7%, 76.7% and 76.6%, respectively. The incidence rates of adverse reactions were 34.8%, 33.5%, 25.7% and 32.1%, respectively. The correlation between the dosing of OXC and LTG with plasma concentration was good(r>0.6), while the correlation for LCM and LEV was poor(r<0.5). The predictive accuracy of LCM, LEV, OXC and LTG plasma concentrations AUC(95%CI)=0.535, 0.579, 0.526, and 0.617 for efficacy in children with epilepsy was higher than that for dose AUC(95%CI)=0.484, 0.488, 0.477, and 0.483. The reference ranges for steady-state plasma concentrations of LCM, LEV, OXC and LTG in children with epilepsy were 2.0~15.0 μg·mL−1, 8.2~124.2 μg·mL−1, 9.8~31.9 μg·mL−1, and 2.1~15.2 μg·mL−1, respectively.
      CONCLUSION It is necessary to regularly monitor the plasma concentrations of LCM, LEV, OXC and LTG in children with epilepsy in a clinical setting to ensure they are maintained within the therapeutic range, facilitating timely adjustments in medication dosage to prevent drug accumulation and reduce the incidence of adverse reactions.

       

      • HTML全文
      • 参考文献(29)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回